Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy
Completed
- Conditions
- Prostate Cancer
- Registration Number
- NCT00692874
- Lead Sponsor
- AstraZeneca
- Brief Summary
This is an open label, non-interventional quality of life analysis for Zoladex treated prostate cancer patients by investigator's questionnaire
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1646
Inclusion Criteria
- Provision of informed consent
- Early or locally-advanced prostate cancer patients on androgen deprivation therapy
- Investigators are requested to recruit patients only with at least 1 month prior Zoladex treatment.
Read More
Exclusion Criteria
- Allergy to substance of medication
- Prostate cancer patients with advanced disease
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Elements of a general and three disease-specific investigator questionnaire Quarterly (plus or minus 3 days )
- Secondary Outcome Measures
Name Time Method Investigator Assessment Report Yearly (plus or minus 1 week )
Trial Locations
- Locations (1)
Research Site
ðŸ‡ðŸ‡ºZalaegerszeg, Hungary